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Abstract
Background: The risk compensation theory is a widely used concept in transport economics to
analyze driver risk behaviour. This article explores the feasibility of applying the theory in blood
transfusion to raise important questions regarding the increased blood safety measures and their
possible effects on blood usage (e.g., the appropriateness in transfusion). Further, it presents the
findings of a pilot survey of physicians in Canada.
Discussion: While studies have attempted to define transfusion appropriateness, this article
argues that if the risk compensation theory holds true for transfusion practice, physicians may
actually be transfusing more. This may increase the possibility of contracting other unknown risks,
such as the variant Creutzfeldt-Jakob Disease (vCJD), as well as increasing the risk of non-infectious
transfusion risks, such as transfusion reactions.
Summary: A much larger study involving psychosocial assessment of physician decision making
process to fully assess physician behaviour within the context of risk compensation theory and
transfusion practice in Canada is needed to further explore this area.
Background
The risk compensation theory postulates that, in perform-
ing any action, people accept a certain level of 'subjec-
tively' estimated risk of the outcome associated with the
action, and compensate the level of risk with an expected
level of benefit they hope to gain from that action [1]. In
other words, people try to equate the probability of a risky
outcome with that of a beneficial outcome [1]. In reality,
people seldom rate their risk subjectively before commit-
ting any action, and then compare that risk value with the
posterior or experienced risk value while performing the
action. Instead, they continually perform risk rating by
updating the risk information, and compare this posterior
risk value with the amount of risk they were originally
willing to accept (i.e., the prior risk value) [1,2]. Typically,
if the posterior risk is lower than the prior risk people tend
to engage in actions that de facto increase their risk expo-
sure; and if the posterior risk value is higher than the prior
risk value people tend to exercise caution and reduce their
risk exposure.
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The theory has been widely applied in transport econom-
ics to assess safety improvement measures in passenger
vehicles, and to perform outcome analysis concerning
driver risk behaviour. Studies suggest that increased safety
measures in vehicles lead to increased driver exposure to
risks, which in turn, leads to increased fatal outcomes [1-
4]. These studies suggest that people consume roughly all
the enhanced safety imposed upon them in other desira-
ble yet risky activities, such as more exciting driving, to
fight boredom.
Further, the theory has also been applied in health eco-
nomics to manage health insurance related risk pooling
and in the area of occupational health [5-8].
How about risk compensation in blood 
transfusion?
The blood system in Canada has undergone various
changes to make the blood system safer than ever before.
Safety measures based on precautionary principles have
been put in place and surveillance of the blood system has
improved significantly. The blood operators, in their mis-
sion statements, clearly state that their utmost task is to
ensure the safety of blood. Consequently, they have intro-
duced several quality assurance procedures (e.g., Nucleic
Acid Amplification Technology (NAT) testing for HIV and
Hepatitis-C, Human T-Lymphotropic Virus (HTLV) test,
universal leukoreduction of blood, rejection of blood unit
indicating initial 'false positive' result, etc.) to bolster pub-
lic confidence in the blood system. In addition, the blood
operators have introduced a donor deferral policy since
October 1999 to protect the blood supply from theoreti-
cal contamination from variant Creutzfeldt-Jakob disease
(vCJD). Finally, the blood operators in Canada have
introduced a NAT-based test to detect West Nile Virus
(WNV) since July 2003 [9].
The risk compensation theory, if applied, implies that
these safety measures may provide positive signals to phy-
sicians across Canada, and may enable physicians to form
a prior belief about the safety of blood. This prior belief
may actually lead physicians to adopt a liberal transfusion
regime until they face a new risk value when they may
alter their behaviour. In other words, physicians may tend
to transfuse more due to increased blood safety measures
since physicians' posterior risks associated with blood
transmissible diseases gradually diminish. This belief is
further reinforced with decreasing risk of HIV and Hepati-
tis-C associated with transfusion [10,11]. All these reasons
may give rise to increased transfusion, which may increase
the risk of contracting other unknown infectious risks.
Increased transfusion could also lead to harm due to non-
infectious risks, such as transfusion reactions [12].
One way to empirically test the applicability of the theory
is to analyze blood utilization figures before and after the
blood system reorganization. However, since there is no
data available on blood utilization in Canada at present,
we used the data on blood collection as a proxy since the
demand for and supply of blood are (or at least have
been) closely matched [13]. Collection figures suggest
that the number of blood units collected during the late
1980s was over 1.2 million a year and the number
dropped to less than 700,000 a year by 1995, and has
since increased. It stood at around 1 million (CBS and
Héma-Québec combined) by the end of 2000 [13]. Con-
sidering that there was likely to have been no significant
difference in the patient population over this time that
would have required greater usage of blood and blood
products, we may hypothesize that the introduction of
safety measures might have assured the physician com-
munity that blood was safer and therefore increased the
use of blood. However, this approach of looking at the
issue is very broad and does not take into account the
individual physician's decision making process and many
other possible confounders such as exogenous demand
and supply side shocks, blood system policy shifts, loss of
donor confidence and the introduction of blood safety
and donor deferral policies. An example of the effect of
such factors was demonstrated by Brecher and Good-
nough, who indicated that improved haemovigilance in
the US may have reduced the use of pre-donated autolo-
gous blood [14].
Another area of interest where there has been an exponen-
tial increase in use is the human plasma derived intrave-
nous immunoglobulin (IVIG), a commercial blood
product where users may be subject to commercial mar-
keting techniques. The use of IVIG, which is indicated for
over 100 indications, has increased manifold during the
past few years [15]. Although there exist clear clinical ben-
efits in using the IVIG for some indications, there remain
many 'grey' areas where the use has not been proven to be
clinically beneficial [16]. Notwithstanding these, the use
of IVIG has been growing unabated and the cost associ-
ated with it is fast increasing. Alike blood, IVIG may also
be subject to risk compensation theory for its increased
utilisation.
Pilot survey of blood and blood products users
In order to better understand physician behaviour sur-
rounding the safety of blood and blood products, and to
test the validity of the hypothesis that "improved blood
safety increases the use of blood by physicians", we con-
ducted a telephone interview of 45 physicians across Can-
ada. Respondents were selected randomly from the list of
names and contact details for internists, cardiovascular
surgeons and haematologists available from the Canadian
Medical Association Directory 2002. There were 27BMC Public Health 2004, 4 http://www.biomedcentral.com/1471-2458/4/20
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respondents from Ontario, 10 from Alberta, four from
Nova Scotia, two each from British Columbia and
Québec. Of the 45 physicians responded, 28 were
internists, 10 were cardiovascular surgeons, and seven
were haematologists.
The survey asked the following five questions each of
which had three possible choices: "yes", "no" and
"unsure":
Question 1: Do you think the safety of blood and blood
products in Canada has increased and improved since the
Krever Commission Report?
Question 2: Do you have confidence over the Canadian
blood system in terms of its safety?
Question 3: Do you think the increased and improved
safety of blood and blood products may influence you to
increase blood utilisation (in clinically appropriate situa-
tions)?
Question 4: Have you increased the usage of blood and
blood products during the past five years?
Question 5: Will you be concerned about and hence
decrease your level of blood and blood products utiliza-
tion if there is any new viral and/or bacterial threat to
blood?
The findings indicate that the majority (N = 43, ~96%) of
respondents think that the safety of blood and blood
products in Canada has increased and improved since the
Krever Commission report in 1997. Around 93% (N = 42)
of the respondents indicated that they have confidence
over the safety of the Canadian blood system. Thirty
respondents (~67%) indicated that their prescribing pat-
tern might be influenced by increased and improved
safety of blood and blood products, while 13 (~29%)
replied negatively and two were not sure (~4%). About
80% (N = 36) of respondents suggested that their usage of
blood and blood products increased over the past five
years, and around 93% (N = 42) of respondents opined
that they would be concerned about and therefore reduce
the level of blood and blood products utilization follow-
ing a new viral and/or bacterial threat in the future.
Discussion
We have explored the possibility of applying the risk com-
pensation theory in blood transfusion practice. If applied,
the risk compensation theory suggests that safety meas-
ures may possibly increase the utilization of blood and
lead to unnecessary transfusion that may defeat the over-
all aim for achieving appropriateness in transfusion. There
were several limitations of our analysis: a) we had a very
limited sample of physicians in our survey; b) we did not
consider the public's perception of safety of blood; and c)
risks of serious hazards of transfusion were not consid-
ered. Further we could not ascertain the degree to which
physicians might be influenced by such increased safety
measures. This requires a much larger study involving psy-
chosocial assessment of physician decision making to
fully assess physician behaviour within the context of risk
compensation theory and transfusion practice in Canada.
Notwithstanding these limitations, we have shown that
physicians might be influenced in their utilisation by the
increased and improved safety of blood and blood prod-
ucts. Blood systems should consider monitoring for such
an effect when introducing new safety measures. Further-
more, they should bear in mind the importance of pre-
venting unnecessary transfusion to reduce non-infectious
risks and unknown infectious risks.
Summary
This pilot study has indicated that the framework used to
analyze risk behaviour within the risk compensation the-
ory could be extended and applied in the blood transfu-
sion discipline to assess physician behaviour in Canada.
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